Page 86 - 2022-06-中国全科医学
P. 86

http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn  ·723·


               1288-1291.                                           10.2337/diacare.28.8.1856.
               YANG J,ZHAO Z B,WU L,et al. Effect of intensive insulin   [17]ERSÖZ H O,UKINC K,KÖSE M,et al. Subcutaneous lispro and
               therapy on secretagogin plasma levels in newly diagnosed non-obese   intravenous regular insulin treatments are equally effective and safe
               type 2 diabetes mellitus patients[J]. J Pract Med,2019,35(8):  for the treatment of mild and moderate diabetic ketoacidosis in adult
               1288-1291.                                           patients[J]. Int J ClinPract,2006,60(4):429-433. DOI:
           [10]林秀红,熊稀霖,徐明彤,等 . 新诊断型糖尿病患者血脂比值                        10.1111/j.1368-5031.2006.00786.x.
               特点及短期胰岛素强化治疗对其影响[J]. 实用医学杂志,                    [18]KAROLI R,FATIMA J,SALMAN T,et al. Managing diabetic
               2017,33(11):1781-1785.                               ketoacidosis in non-intensive care unit setting:Role of insulin
               LIN X H,XIONG X L,XU M T,et al. Features of lipid ratios in   analogs[J]. Indian J Pharmacol,2011,43(4):398-401.
               patients with newly diagnosed T2DM and effects of intensive insulin   DOI:10.4103/0253-7613.83109.
               treatment on them[J]. J Pract Med,2017,33(11):1781-  [19]UMPIERREZ G E,LATIF K,STOEVER J,et al. Efficacy of
               1785.                                                subcutaneous insulin lispro versus continuous intravenous regular
           [11]栾晓军,陈劲松,陈小雨,等 . 胰岛素泵联合速效胰岛素类似                        insulin for the treatment of patients with diabetic ketoacidosis[J].
               物治疗糖尿病酮症酸中毒疗效观察[J]. 内科急危重症杂志,                        Am  J  Med,2004,117(5):291-296.  DOI:10.1016/j.
               2005,11(4):161-163.                                  amjmed.2004.05.010.
               LUAN X J,CHEN J S,CHEN X Y,et al. Clinical observation of   [20]UMPIERREZ  G  E,CUERVO  R,KARABELL  A,et  al.
               continuous subcutaneous insulin aspart infusion therapy in patients   Treatment of diabetic ketoacidosis with subcutaneous insulin
               with diabetic ketoacidosis[J]. J Intern Intensive Med,2005,11   aspart[J]. Diabetes Care,2004,27(8):1873-1878. DOI:
                                                                    10.1007/s12020-018-1635-z.
               (4):161-163.
                                                               [21]SCHUMANN C,FAUST M. Diabetic ketoacidosis and hyperosmolar
           [12]KITABCHI  A  E,UMPIERREZ  G  E,MILES  J  M,et  al.
                                                                    hyperglycemic state[J]. Dtsch Med Wochenschr,2018,143(6):
               Hyperglycemic crises in adult patients with diabetes[J]. Diabetes
                                                                    384-391. DOI:10.1055/s-0043-114493.
               Care,2009,32(7):1335-1343. DOI:10.2337/dc09-9032.
                                                               [22]ROACH P. New insulin analogues and routes of delivery:
           [13]NYENWE E A,KITABCHI A E. Evidence-based management
                                                                    pharmacodynamic  and  clinical  considerations[J].  Clin
               of hyperglycemic emergencies in diabetes mellitus[J]. Diabetes
                                                                    Pharmacokinet,2008,47(9):595-610.  DOI:
               Res Clin Pract,2011,94(3):340-351. DOI:10.1016/j.
                                                                    10.2165/00003088-200847090-00003.
               diabres.2011.09.012.
                                                               [23]PETERS A L,AHMANN A J,BATTELINO T,et al. Diabetes
           [14]FISHER  J  N,SHAHSHAHANI  M  N,KITABCHI  A  E.
                                                                    technology-continuous subcutaneous insulin infusion therapy and
               Diabetic ketoacidosis:low-dose insulin therapy by various
                                                                    continuous glucose monitoring in adults:an endocrine society
               routes[J]. N Engl J Med,1977,297(5):238-241. DOI:
                                                                    clinical practice guideline[J]. J Clin Endocrinol Metab,2016,
               10.1056/NEJM197708042970502.
                                                                    101(11):3922-3937. DOI:10.1210/jc.2016-2534.
           [15]ANDRADE-CASTELLANOS C A,COLUNGA-LOZANO L E,
                                                               [24]中华医学会糖尿病学分会 . 中国 2 型糖尿病防治指南(2017
               DELGADO-FIGUEROA N,et al. Subcutaneous rapid-acting
                                                                    年版)[J].  中国实用内科杂志,2018,38(4):292-344.
               insulin analogues for diabetic ketoacidosis[J]. Cochrane Database
                                                                    DOI:10.19538/j.nk2018040108.
               Syst Rev,2016 (1):CD011281. DOI:10.1002/14651858.
                                                                    Chinese Diabetic Society. Guidelines for the prevention and control
               CD011281.pub2.
                                                                    of type 2 diabetes in China(2017 edition)[J]. Chin J Pract
           [16]DELLA MANNA T,STEINMETZ L,CAMPOS P R,et al.
                                                                    Intern Med,2018,38(4):292-344. DOI:10.19538/j.
               Subcutaneous use of a fast-acting insulin analog:an alternative
                                                                    nk2018040108.
               treatment for pediatric patients with diabetic ketoacidosis[J].
                                                                          (收稿日期:2021-08-23;修回日期:2021-10-13)
               Diabetes  Care,2005,28(8):1856-1861.  DOI:                                      (本文编辑:贾萌萌)
           (上接第 718 页)                                              triglyceride and risk of hyperuricemia[J]. Lipids Health Dis,
           [19]MURPHY A J,WOOLLARD K J,HOANG A,et al. High-         2019,18(1):147. DOI:10.1186/s12944-019-1077-5.
               density lipoprotein reduces the human monocyte inflammatory   [22]YU X L,SHU L,SHEN X M,et al. Gender difference on
               response[J]. Arterioscler Thromb Vasc Biol,2008,28(11):  the relationship between hyperuricemia and nonalcoholic fatty
               2071-2077. DOI:10.1161/ATVBAHA.108.168690.           liver disease among Chinese:an observational study[J].
                                                                    Medicine (Baltimore),2017,96(39):e8164. DOI:
           [20]PARTHASARATHY S,BARNETT J,FONG L G. High-density
                                                                    10.1097/MD.0000000000008164.
               lipoprotein inhibits the oxidative modification of low-density
                                                               [23]WALLACE I R,MCKINLEY M C,BELL P M,et al. Sex hormone
               lipoprotein[J]. Biochim Biophys Acta,1990,1044(2):
                                                                    binding globulin and insulin resistance[J]. Clin Endocrinol:
               275-283. DOI:10.1016/0005-2760(90)90314-n.
                                                                    Oxf,2013,78(3):321-329. DOI:10.1111/cen.12086.
           [21]ZHANG L,WAN Q L,ZHOU Y M,et al. Age-related and            (收稿日期:2021-07-03;修回日期:2021-10-12)
               gender-stratified differences in the association between high                   (本文编辑:贾萌萌)
   81   82   83   84   85   86   87   88   89   90   91